<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340440</url>
  </required_header>
  <id_info>
    <org_study_id>0302764</org_study_id>
    <nct_id>NCT04340440</nct_id>
  </id_info>
  <brief_title>Curative D2 vs D1 Lymphadenectomy in Operable Gastric Carcinoma</brief_title>
  <official_title>Surgical and Oncologic Outcomes After Curative D2 vs D1 Gastrectomy in Operable Gastric Carcinoma, A Randomized Controlled Study in Egyptian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric carcinoma is the second most common cause of cancer-related deaths and its main
      treatment modality if potentially curable is surgery but the optimal surgical resection is
      controversial. The aim of the current study was to assess the outcomes of curative D2
      compared to D1 gastrectomy of operable gastric carcinoma regarding postoperative morbidity
      and mortality, disease recurrence and survival rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 consecutive patients with potentially operable gastric carcinoma were randomized via
      concealed envelopes into 2 groups (each included 40 patients), group I managed by radical
      gastrectomy with D1 lymphadenectomy while group II managed by radical gastrectomy with D2
      lymphadenectomy . Both groups were compared regarding postoperative mortality, morbidities,
      tumor recurrence and 2 years survival rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Randomization by opaque sealed envelopes</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative morbidity rate</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Frequency of early postoperative complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Operative mortality rate</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>Frequency of early postoperative mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 years Recurrence rate</measure>
    <time_frame>2 years after surgery</time_frame>
    <description>Frequency of tumor recurrence within 2 years after curative surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 years Cancer specific mortality rate</measure>
    <time_frame>2 years after surgery</time_frame>
    <description>Frequency of patients died because of gastric cancer within 2 years after curative surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 years Disease free survival rate</measure>
    <time_frame>2 years after surgery</time_frame>
    <description>Percentage of patients survived for 2 years without tumor recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 years Overall survival rate</measure>
    <time_frame>2 years after surgery</time_frame>
    <description>Percentage of patients survived for 2 years with/without tumor recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>D1 lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D1 lymphadenectomy</intervention_name>
    <description>Radical gastrectomy with D1 lymphadenectomy</description>
    <arm_group_label>D1 lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 lymphadenectomy</intervention_name>
    <description>Radical gastrectomy with D2 lymphadenectomy</description>
    <arm_group_label>D2 lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed gastric carcinoma

          -  Potentially operable gastric carcinoma without evidence of distant metastasis

        Exclusion Criteria:

          -  Complicated gastric cancer (obstructed or perforated)

          -  Locally irresectable tumor

          -  Previous or coexisting cancer

          -  Prior gastric surgery or neoadjuvant chemotherapy

          -  Contraindication for major surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004 Jun 1;22(11):2069-77. Epub 2004 Apr 13.</citation>
    <PMID>15082726</PMID>
  </reference>
  <reference>
    <citation>Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006 Apr;7(4):309-15.</citation>
    <PMID>16574546</PMID>
  </reference>
  <reference>
    <citation>Tamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745. doi: 10.1155/2011/748745. Epub 2011 Jun 14.</citation>
    <PMID>22312521</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Mohamed El Messiry</investigator_full_name>
    <investigator_title>Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>Operable gastric cancer</keyword>
  <keyword>D2 vs D1 lymphadenectomy</keyword>
  <keyword>Surgical and Oncologic outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

